Non small cell lung cancer medical therapy
|
Non Small Cell Lung Cancer Microchapters |
|
Differentiating Non Small Cell Lung Cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Non small cell lung cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Non small cell lung cancer medical therapy |
|
Directions to Hospitals Treating Non small cell carcinoma of the lung |
|
Risk calculators and risk factors for Non small cell lung cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2] Maria Fernanda Villarreal, M.D. [3]
Overview
Chemotherapy is indicated for non-small cell lung cancer stage (> IIA, B, III) as adjuvant therapy and for I, II as first line therapy. However, the predominant therapy for non-small cell lung cancer is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of non-small cell lung cancer.
Medical Therapy
- Chemotherapy is indicated for early stage non-small cell lung cancer
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of treatment for non-small cell lung cancer
- Other chemotherapy regimens, such as: cyclophosphamide, doxorubicin (adriamycin), and vincristine may be an alternative for non-small cell lung cancer patients who are unable to tolerate a platinum-based chemotherapy
Complications
- Medical therapy complications for non-small cell lung cancer will depend on the chemotherapeutic agent
- Common chemotherapy complications, include:
- Platinum-based chemotherapy
- The main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapy complications, include:
- Extravasation